Design, synthesis and biological evaluation of bitopic arylpiperazine-hexahydro-pyrazinoquinolines as preferential dopamine D3 receptor ligands
Authors:
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 77, 125-135
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20161438)
This publication has 34 references indexed in Scilit:
- The novel dopamine D3 receptor antagonist, SR 21502, reduces cocaine conditioned place preference in ratsNeuroscience Letters, 2014
- Reduction of Cocaine Self-Administration and D3 Receptor-Mediated Behavior by Two Novel Dopamine D3 Receptor-Selective Partial Agonists, OS-3-106 and WW-III-55The Journal of Pharmacology and Experimental Therapeutics, 2013
- Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptorsEuropean Journal of Medicinal Chemistry, 2013
- Dopamine D1, D2, D3 Receptors, Vesicular Monoamine Transporter Type-2 (VMAT2) and Dopamine Transporter (DAT) Densities in Aged Human BrainPLOS ONE, 2012
- The effects of the preferential dopamine D3 receptor antagonist S33138 on ethanol binge drinking in C57BL/6J miceSynapse, 2012
- Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agentsMolecular Psychiatry, 2012
- Imaging brain regional and cortical laminar effects of selective D3 agonists and antagonistsPsychopharmacology, 2010
- Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapineNature, 1991
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990
- Multiple receptors for dopamineNature, 1979